ClinicalTrials.gg
CompletedNCT02023879Updated Jul 27, 2018Results posted

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

A Phase 3 interventional study of Alirocumab and Placebo (for Alirocumab) in Hypercholesterolemia, sponsored by Sanofi. Completed at 43 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-27.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
233
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
16th of 43
233 · median 107
Started
2013
with 5 others
Phase 3
20 of 43
none open now
Registered
26th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 16th largest by enrollment, is one of 6 that started in 2013, is one of 20 in phase 3, and was the 26th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by a regimen of Alirocumab including a starting dose of 150 mg every 4 weeks (Q4W) as add-on to non-statin lipid modifying background therapy or as monotherapy in comparison with placebo in participants with primary hypercholesterolemia not treated with a statin.

Secondary Objective:

  • To evaluate the effects on other lipid parameters of Alirocumab 150 mg Q4W versus placebo.
  • To evaluate the safety and tolerability of Alirocumab 150 mg Q4W.

Alirocumab 75 mg Q2W was added as a calibrator arm.

Read the detailed description

The core study duration was approximately 35 weeks per participant (screening: 3 weeks, double-blind treatment period: 24 weeks; follow-up: 8 weeks). Participants who successfully completed the treatment period had the possibility to participate in an optional open-label treatment period with Alirocumab 150 mg Q4W until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants with primary hypercholesterolemia (heterozygous familial hypercholesterolemia [heFH] or non-FH) not adequately controlled with their non-statin LMT (either ezetimibe or fenofibrate) or diet alone.

Exclusion criteria

Exclusion criteria:

  • LDL-C \<70 mg/dL (1.81 mmol/L) at screening for statin intolerant participants at very high cardiovascular (CV) risk;
  • LDL-C \<100 mg/dL (\<2.59 mmol/L) at screening for statin intolerant participants at high or moderate CV risk or, participants not fulfilling the statin intolerant definition at moderate CV risk;
  • LDL-C ≥160 mg/dL (≥4.1 mmol/L) at screening for participants receiving diet only or, participants not fulfilling the statin intolerant definition at moderate CV risk and receiving a non-statin LMT.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
233 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Period 1: Placebo (for Alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks. Period 2: Alirocumab 150 mg SC injection every 4 weeks (Q4W) from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and low-density lipoprotein cholesterol (LDL-C) values. Subsequent down titration to 150 mg Q4W was allowed.

    Drug: Alirocumab · Drug: Placebo (for Alirocumab) · Drug: Non-statin LMT · Other: Diet Alone

  • Other
    Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)

    Period 1: Alirocumab 75 mg SC injection Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or \<30% LDL-C reduction from baseline. Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed.

    Drug: Alirocumab · Drug: Non-statin LMT · Other: Diet Alone

  • Experimental
    Alirocumab 150 mg Q4W/Up to 150 mg Q2W

    Period 1: Alirocumab 150 mg SC injection Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or \<30% LDL-C reduction from baseline. Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed.

    Drug: Alirocumab · Drug: Placebo (for Alirocumab) · Drug: Non-statin LMT · Other: Diet Alone

Interventions

  • Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).

    Also known as: SAR236553, REGN727, Praluent®

  • DrugPlacebo (for Alirocumab)

    Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).

  • DrugNon-statin LMT

    Ezetimibe or Fenofibrate at stable dose as background therapy.

  • OtherDiet Alone

    Stable cholesterol-lowering diet as background therapy.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)

    Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).

    Time frame: From Baseline to Week 24

  2. Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  3. Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 24

  4. Percent Change From Baseline in Calculated LDL-C to Averaged Weeks 9 to 12 - ITT- Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points.

    Time frame: From Baseline to Week 24

  5. Percent Change From Baseline in Calculated LDL-C at Averaged Week 9 to 12 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points.

    Time frame: From Baseline to Week 24

  6. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  7. Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 24

  8. Percent Change From Baseline in Non-HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  9. Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 24

  10. Percent Change From Baseline in Total-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  11. Percent Change From Baseline in Apo B at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  12. Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  13. Percent Change From Baseline in Total-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  14. Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C <100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis

    Moderate CV risk: 10-year fatal cardiovascular disease (CVD) risk Systemic Coronary Risk Evaluation (SCORE) ≥1 and \<5%. High CV risk: 10-year fatal CVD risk SCORE ≥5% or moderate chronic kidney disease or type 1 or type 2 diabetes mellitus without target organ damage or familial hypercholesterolemia. Very high CV risk: history of documented coronary heart disease, ischemic stroke, peripheral artery disease, transient ischemic attack, abdominal aortic aneurysm, or carotid artery occlusion \>50% without symptoms; carotid endarterectomy or carotid artery stent procedure; renal artery stenosis, or renal artery stent procedure; or type 1 or type 2 diabetes mellitus with target organ damage. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included.

    Time frame: From Baseline to Week 24

  15. Percentage of Very High CV Risk Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C< 100 mg/dL (<2.59 mmol/L) at Week 24 - On-treatment Analysis

    Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 24

  16. Percentage of Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 from last observation carried forward (LOCF) approach including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  17. Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) at Week 24 - On-treatment Analysis

    Adjusted percentages at Week 24 from LOCF approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 24

  18. Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  19. Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  20. Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  21. Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  22. Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  23. Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  24. Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  25. Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

Other outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 32, 36, 48, 72, 96, 120, 144, 168 On-Treatment Analysis in Open Label Extension Treatment Phase

    Mean percent changes (and standard deviations) observed during the open-label extension period are provided.

    Time frame: Baseline, Week 32, 36, 48, 72, 96, 120, 144 and Week 168

07

Results

Posted Mar 15, 2017
Limitations and caveats
The systematic randomization error was not anticipated to have an impact on the power of the study. The sample size to detect a difference in efficacy endpoints was reached (it was increased to obtain additional safety data) and blind was maintained.

Participant flow

The study was conducted at 43 centers in 8 countries. A total of 402 participants were screened between December-2013 and May-2014, of whom 233 were randomized for double-blind (DB) treatment period and 169 were screen failures. Out of 233 randomized for DB period, 205 participants entered the optional open-label (OL) extension period.

Period 1: 24-Week Double-blind Treatment
Participant flow — Period 1: 24-Week Double-blind Treatment
MilestonePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)Alirocumab 150 mg Q4W/Up to 150 mg Q2W
Started5811659
Treated5811558
Completed5410750
Not completed499
Withdrew: Adverse event225
Withdrew: Poor compliance to protocol021
Withdrew: Physician decision010
Withdrew: Consent withdrawn by participant101
Withdrew: Randomized but not treated011
Withdrew: Other than specified above131
Extension Open Label Treatment
Participant flow — Extension Open Label Treatment
MilestonePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)Alirocumab 150 mg Q4W/Up to 150 mg Q2W
Started5110648
Completed468943
Not completed5175
Withdrew: Adverse event173
Withdrew: Poor compliance to protocol110
Withdrew: Participant moved120
Withdrew: Other than specified above272

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)

Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)Alirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)4.7 ± 2.3-53.5 ± 1.6-51.7 ± 2.3
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Least square (ls) mean difference: -56.4 · 95% CI -62.9 to -49.9Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis5.1 ± 2.1-55.3 ± 1.5-54.6 ± 2.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -59.7 · 95% CI -65.6 to -53.8Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis3.2 ± 2.5-50.8 ± 1.7-41.7 ± 2.4
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -44.9 · 95% CI -51.8 to -38.1Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis3.6 ± 2.3-51.5 ± 1.6-44.8 ± 2.3
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -48.4 · 95% CI -54.8 to -41.9Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C to Averaged Weeks 9 to 12 - ITT- Analysis

Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C to Averaged Weeks 9 to 12 - ITT- Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C to Averaged Weeks 9 to 12 - ITT- Analysis3.2 ± 2.0-53.6 ± 1.4-52.3 ± 2.0
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -55.5 · 95% CI -61.1 to -49.8Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Averaged Week 9 to 12 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Averaged Week 9 to 12 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Averaged Week 9 to 12 - On-Treatment Analysis3.6 ± 1.9-54.1 ± 1.3-55.0 ± 1.9
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -58.6 · 95% CI -63.8 to -53.4Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis7.5 ± 2.1-39.7 ± 1.5-38.9 ± 2.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -46.4 · 95% CI -52.4 to -40.4Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Apo B at Week 24 - On-treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis7.7 ± 2.0-41.2 ± 1.4-40.9 ± 2.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -48.6 · 95% CI -54.3 to -42.8Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 24 - ITT Analysis4.8 ± 2.1-45.3 ± 1.5-44.2 ± 2.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -49.0 · 95% CI -54.9 to -43.2Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis5.0 ± 1.9-46.9 ± 1.3-46.7 ± 1.9
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -51.7 · 95% CI -57.1 to -46.4Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Total-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Total-C at Week 24 - ITT Analysis3.0 ± 1.6-34.0 ± 1.1-32.3 ± 1.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -35.3 · 95% CI -39.8 to -30.8Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Apo B at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis7.0 ± 2.2-38.4 ± 1.6-31.3 ± 2.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -38.2 · 95% CI -44.3 to -32.1Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis3.0 ± 2.2-43.4 ± 1.5-34.9 ± 2.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -37.9 · 95% CI -43.9 to -31.8Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Total-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis1.8 ± 1.6-32.6 ± 1.2-24.5 ± 1.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -26.3 · 95% CI -30.9 to -21.7Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C <100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis

Moderate CV risk: 10-year fatal cardiovascular disease (CVD) risk Systemic Coronary Risk Evaluation (SCORE) ≥1 and \<5%. High CV risk: 10-year fatal CVD risk SCORE ≥5% or moderate chronic kidney disease or type 1 or type 2 diabetes mellitus without target organ damage or familial hypercholesterolemia. Very high CV risk: history of documented coronary heart disease, ischemic stroke, peripheral artery disease, transient ischemic attack, abdominal aortic aneurysm, or carotid artery occlusion \>50% without symptoms; carotid endarterectomy or carotid artery stent procedure; renal artery stenosis, or renal artery stent procedure; or type 1 or type 2 diabetes mellitus with target organ damage. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included.

Time frame:
From Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C <100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C <100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis1.870.363.9
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 279.8 · 95% CI 29.1 to 2690.1Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercentage of Very High CV Risk Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C< 100 mg/dL (<2.59 mmol/L) at Week 24 - On-treatment Analysis

Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C< 100 mg/dL (<2.59 mmol/L) at Week 24 - On-treatment Analysis
percentage of participantsPlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percentage of Very High CV Risk Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C< 100 mg/dL (<2.59 mmol/L) at Week 24 - On-treatment Analysis1.872.767.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 354.7 · 95% CI 36.2 to 3479.5Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercentage of Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 from last observation carried forward (LOCF) approach including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percentage of Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) at Week 24 - ITT Analysis0.060.050.0
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 126.0 · 95% CI 20.0 to 9999Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo (Confidence interval should be read as 20.0 to \>9999)
SecondaryPercentage of Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) at Week 24 - On-treatment Analysis

Adjusted percentages at Week 24 from LOCF approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) at Week 24 - On-treatment Analysis
percentage of participantsPlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) at Week 24 - On-treatment Analysis0.061.750.9
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 141.5 · 95% CI 22.2 to 9999Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo (Confidence interval should be read as 20.0 to \>9999)
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis4.1 ± 3.7-21.8 ± 2.6-15.5 ± 3.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Regression, Robust · p = 0.0002 (Threshold for significance at 0.05 level.) · Adjusted mean difference: -19.6 · 95% CI -29.8 to -9.4Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis2.2 ± 3.4-16.5 ± 2.4-5.7 ± 3.3
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q4W/Up to 150 mg Q2W · Regression, Robust · p = 0.0892 (Threshold for significance at 0.05 level.) · Adjusted mean difference: -7.9 · 95% CI -17.1 to 1.2Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis-2.4 ± 1.97.4 ± 1.47.7 ± 2.0
SecondaryPercent Change From Baseline in HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis-0.8 ± 1.96.8 ± 1.38.6 ± 1.9
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis1.1 ± 3.8-10.6 ± 2.7-9.2 ± 3.9
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis2.1 ± 3.9-11.3 ± 2.7-3.0 ± 3.8
SecondaryPercent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis3.4 ± 1.58.2 ± 1.110.0 ± 1.5
SecondaryPercent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2WAlirocumab 150 mg Q4W/Up to 150 mg Q2W
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis2.6 ± 1.55.9 ± 1.17.6 ± 1.5
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 32, 36, 48, 72, 96, 120, 144, 168 On-Treatment Analysis in Open Label Extension Treatment Phase

Mean percent changes (and standard deviations) observed during the open-label extension period are provided.

Time frame:
Baseline, Week 32, 36, 48, 72, 96, 120, 144 and Week 168
Reported as:
Mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 32, 36, 48, 72, 96, 120, 144, 168 On-Treatment Analysis in Open Label Extension Treatment Phase
percent changeAlirocumab 150 mg Q4W (After Placebo Q2W)Alirocumab 150 mg QW4 (After Alirocumab 75 Q2W/Up 150 Q2W)Alirocumab 150 mg Q4W (After Alirocumab 150 Q4W/Up 150 Q2W)
Week 32-37.3 ± 18.8-41.1 ± 21.2-46.9 ± 13.3
Week 36-36.1 ± 22.0-39.2 ± 21.2-43.1 ± 13.7
Week 48-46.5 ± 24.2-49.2 ± 18.7-48.7 ± 21.7
Week 72-50.8 ± 20.6-53.7 ± 19.5-52.3 ± 21.3
Week 96-49.8 ± 20.4-52.8 ± 19.6-46.8 ± 22.0
Week 120-50.6 ± 20.9-53.7 ± 18.7-51.8 ± 24.1
Week 144-52.7 ± 17.6-48.7 ± 23.7-49.4 ± 20.9
Week 168-47.8 ± 24.2-66.2 ± 17.1-60.0 ± 4.6

Adverse events

Collected over All Adverse Events (AE) were collected from signature of informed consent form up to study completion (up to 176 weeks) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W0/58 (0%)4/58 (6.9%)28/58 (48.3%)
Alirocumab 75 mg Q2W/Up150 mg Q2W0/115 (0%)7/115 (6.1%)61/115 (53%)
Alirocumab 150 mg Q4W/Up150 mg Q2W0/58 (0%)7/58 (12.1%)29/58 (50%)
Alirocumab 150 mg Q4W (After Placebo Q2W)0/51 (0%)15/51 (29.4%)42/51 (82.4%)
Alirocumab 150 mg Q4W (After Alirocumab 75 Q2W/Up150 Q2W)2/106 (1.9%)28/106 (26.4%)71/106 (67%)
Alirocumab 150 mg Q4W (After Alirocumab 150 Q4W/Up150 Q2W)1/48 (2.1%)14/48 (29.2%)31/48 (64.6%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventPlacebo Q2WAlirocumab 75 mg Q2W/Up150 mg Q2WAlirocumab 150 mg Q4W/Up150 mg Q2WAlirocumab 150 mg Q4W (After Placebo Q2W)Alirocumab 150 mg Q4W (After Alirocumab 75 Q2W/Up150 Q2W)Alirocumab 150 mg Q4W (After Alirocumab 150 Q4W/Up150 Q2W)
PneumoniaInfections and infestations0/581/1150/581/511/1062/48
SyncopeNervous system disorders0/580/1150/580/513/1062/48
FallInjury, poisoning and procedural complications1/580/1150/582/511/1060/48
Acute myocardial infarctionCardiac disorders0/580/1151/580/513/1060/48
Atrial fibrillationCardiac disorders0/580/1150/581/510/1061/48
Cardio-respiratory arrestCardiac disorders0/580/1150/580/510/1061/48
Coronary artery diseaseCardiac disorders0/580/1150/580/512/1061/48
FaecalomaGastrointestinal disorders0/580/1150/580/510/1061/48
Small intestinal obstructionGastrointestinal disorders0/580/1150/580/511/1061/48
CellulitisInfections and infestations0/580/1150/580/510/1061/48
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPlacebo Q2WAlirocumab 75 mg Q2W/Up150 mg Q2WAlirocumab 150 mg Q4W/Up150 mg Q2WAlirocumab 150 mg Q4W (After Placebo Q2W)Alirocumab 150 mg Q4W (After Alirocumab 75 Q2W/Up150 Q2W)Alirocumab 150 mg Q4W (After Alirocumab 150 Q4W/Up150 Q2W)
Viral upper respiratory tract infectionInfections and infestations3/5810/1155/585/5116/1069/48
CoughRespiratory, thoracic and mediastinal disorders0/583/1151/589/519/1061/48
ArthralgiaMusculoskeletal and connective tissue disorders4/588/1157/588/517/1063/48
OsteoarthritisMusculoskeletal and connective tissue disorders2/580/1150/588/517/1063/48
Injection site reactionGeneral disorders0/584/1158/581/517/1067/48
Back painMusculoskeletal and connective tissue disorders0/585/1152/584/5110/1067/48
Upper respiratory tract infectionInfections and infestations4/584/1153/587/518/1064/48
MyalgiaMusculoskeletal and connective tissue disorders3/587/1153/587/516/1061/48
FallInjury, poisoning and procedural complications1/586/1150/586/5114/1062/48
Non-cardiac chest painGeneral disorders3/583/1150/586/515/1061/48

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)Alirocumab 150 mg Q4W/Up to 150 mg Q2WTotal
Mean63.1 ± 10.762.5 ± 9.964.2 ± 10.063.1 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)Alirocumab 150 mg Q4W/Up to 150 mg Q2WTotal
Female274729103
Male316930130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)Alirocumab 150 mg Q4W/Up to 150 mg Q2WTotal
Hispanic or Latino17412
Not Hispanic or Latino5710954220
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)Alirocumab 150 mg Q4W/Up to 150 mg Q2WTotal
American Indian or Alaska Native0000
Asian1438
Native Hawaiian or Other Pacific Islander0101
Black or African American1315
White5610855219
More than one race0000
Unknown or Not Reported0000
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Placebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)Alirocumab 150 mg Q4W/Up to 150 mg Q2WTotal
Mean158.5 ± 47.3154.5 ± 44.6163.9 ± 69.1157.9 ± 52.4
Calculated LDL-C in mmol/L
Calculated LDL-C in mmol/L(mmol/L)Placebo Q2WAlirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)Alirocumab 150 mg Q4W/Up to 150 mg Q2WTotal
Mean4.106 ± 1.2264.002 ± 1.1544.245 ± 1.7894.089 ± 1.356
08

Study locations

43 sites
  • Investigational Site Number 840703
    Beverly Hills, California 90211, United States
  • Investigational Site Number 840704
    Atlantis, Florida 33462, United States
  • Investigational Site Number 840708
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840701
    Sarasota, Florida 34239, United States
  • Investigational Site Number 840706
    Fall River, Massachusetts 02720, United States
  • Investigational Site Number 840705
    Saint Louis, Missouri 63131, United States
  • Investigational Site Number 840707
    Durham, North Carolina 27710, United States
  • Investigational Site Number 840702
    Summerville, South Carolina 29485, United States
  • Investigational Site Number 036703
    Ashford, 5035, Australia
  • Investigational Site Number 036702
    Perth, 6000, Australia
  • Investigational Site Number 036701
    Woolloongabba, 4102, Australia
  • Investigational Site Number 056702
    Antwerpen, 2060, Belgium
  • Investigational Site Number 056703
    Haine-Saint-Paul, 7100, Belgium
  • Investigational Site Number 056701
    Leuven, 3000, Belgium
  • Investigational Site Number 124703
    Chicoutimi, G7H 7P2, Canada
  • Investigational Site Number 124701
    Quebec, G1V 4M6, Canada
  • Investigational Site Number 124704
    Sherbrooke, J1H 1Z1, Canada
  • Investigational Site Number 124706
    Toronto, M9V 4B4, Canada
  • Investigational Site Number 124702
    Vancouver, V5Z 1M9, Canada
  • Investigational Site Number 124705
    Victoria, V8T 5G4, Canada
  • Investigational Site Number 208703
    Aarhus, 8200, Denmark
  • Investigational Site Number 208702
    Esbjerg, 6700, Denmark
  • Investigational Site Number 208701
    Glostrup, 2600, Denmark
  • Investigational Site Number 208704
    Hvidovre, 2650, Denmark
  • Investigational Site Number 208705
    Køge, 4600, Denmark
  • Investigational Site Number 528701
    Amsterdam, 1105 AZ, Netherlands
  • Investigational Site Number 528708
    Den Helder, 1782 GZ, Netherlands
  • Investigational Site Number 528702
    Hoogeveen, 7909 AA, Netherlands
  • Investigational Site Number 528703
    Hoorn, 1625 HV, Netherlands
  • Investigational Site Number 528706
    Rotterdam, 3045 PM, Netherlands
  • Investigational Site Number 528709
    Sneek, 8601 ZK, Netherlands
  • Investigational Site Number 528704
    Utrecht, 3584 CX, Netherlands
  • Investigational Site Number 528707
    Venlo, 5912 BL, Netherlands
  • Investigational Site Number 554702
    Auckland, 1023, New Zealand
  • Investigational Site Number 554701
    Christchurch, 8011, New Zealand
  • Investigational Site Number 724703
    A Coruna, 15006, Spain
  • Investigational Site Number 724707
    Barcelona, 08025, Spain
  • Investigational Site Number 724710
    Barcelona, 08035, Spain
  • Investigational Site Number 724702
    Córdoba, 14004, Spain
  • Investigational Site Number 724705
    Granada, 18012, Spain
  • Investigational Site Number 724709
    Sant Joan Despí, 08970, Spain
  • Investigational Site Number 724706
    Santiago De Compostela, 15706, Spain
  • Investigational Site Number 724701
    Zaragoza, 50009, Spain
09

References and documents

Publications

  • Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Watts GF, Baccara-Dinet MT, Lecorps G, Manvelian G, Farnier M; ODYSSEY CHOICE II Investigators. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. J Am Heart Assoc. 2016 Sep 13;5(9):e003421. doi: 10.1161/JAHA.116.003421. PubMed 27625344 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Oct 2014 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 2 years 4 months after primary completion. A results delay was requested in Oct 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2013
First posted
Dec 30, 2013
Start
Dec 16, 2013
Primary completionActual
Oct 27, 2014
CompletionActual
Jun 30, 2017
Results delay requested
Oct 8, 2015
Results first posted
Mar 15, 2017
Last update
Jul 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02023879
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 30, 2013
Start date
Dec 16, 2013
Primary completion
Oct 27, 2014
Completion
Jun 30, 2017
Results posted
Mar 15, 2017
Last update
Jul 27, 2018

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion